House Dems probe drugmakers over insulin prices

Jan 31, 2019

House Democrats have sent letters to Eli Lilly, Novo Nordisk and Sanofi inquiring about rising insulin prices.

The letters requested information from the drugmakers on pricing and the obstacles to providing more affordable insulin, by February 13. Specifically, the Democrats asked each company the average price for insulin products for the past 10 years, and explanations for increases; the net profits of the companies' insulin products for the past 10 years; and a list of changes made to their insulin products.

The two reps who sent the letters, Pallone (NJ) and DeGette (CO), said they worry about diabetics rationing their insulin because they can't afford to buy more.

Drug pricing remains in the spotlight for lawmakers. Earlier this month, House Oversight Committee Chairman Elijah Cummings, said he sent letters to 12 drugmakers seeking detailed information and documents about the companies' pricing practices.

Read The Hill coverage

Don't miss your Daily Dose.  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments